Скачать с ютуб Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer в хорошем качестве

Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce positive final overall survival data from the company’s Phase 2 clinical trial of its investigational immunotherapy combined with an antiviral agent and standard-of-care (SoC) chemoradiation, followed by surgery, in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The updated results, reflecting an additional nine months of follow-up, demonstrated a durable survival advantage for patients receiving the combination therapy plus SoC compared to SoC alone. Patients treated with the investigational immunotherapy (n=7) achieved an estimated median overall survival of 31.4 months after enrollment, significantly longer than the 12.5 months observed in the control group (n=6). Notably, long-term survivors in the immunotherapy group—alive at 66.0, 63.6, and 35.8 months post-enrollment—experienced disease recurrence but responded to salvage chemotherapy, leading to prolonged post-progression survival, further underscoring the therapy's sustained benefits. Dr. Tak emphasized that pancreatic cancer remains one of the most challenging diseases to treat, as patients with borderline resectable PDAC often harbor undetectable metastases not cleared by current neoadjuvant chemoradiation and surgery. The investigational immunotherapy, designed to stimulate an in situ vaccine-like response against the patient’s tumor, shows potential to improve long-term outcomes and extend survival in this aggressive cancer setting. The U.S. Food and Drug Administration (FDA) has previously granted the therapy Fast Track and Orphan Drug Designations in combination with the antiviral agent for the treatment of PDAC, supporting its expedited development as a promising new treatment option for this devastating disease. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch